Physician profile
Michael Fabbro
NPI 1114244357
$12,480.13
in general payments reported to CMS, 2019-2025
11 companies · $6,285 in 2025
The $6,285 reported for 2025 was more than what 98% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $35.81 · 2021: $691 · 2022: $2,037 · 2023: $1,495 · 2024: $1,465 · 2025: $6,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,477 · Honoraria: $4,000 · Travel and Lodging: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,477.15 |
| Honoraria | $4,000.00 |
| Travel and Lodging | $768.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $5,006.70 | 2025 | Fibryga & Balfaxar |
| Edwards Lifesciences Corporation | $2,543.71 | 2019-2025 | Mitris Resilia Mitral Valve, Inspiris Resilia Aortic Valve |
| Medtronic, INC. | $2,422.37 | 2021-2025 | Avalus, Mosaic, Biomedicus |
| Atricure, INC. | $1,517.99 | 2021-2025 | Synergy Ablation System, Atricure Cryoice Cryoablation System (Cryo2), Atriclip Laa Exclusion System |
| Abbott Laboratories | $473.06 | 2019-2023 | Navitor |
| Medtronic Vascular, INC. | $186.97 | 2019 | |
| Hemosonics LLC | $95.72 | 2022 | |
| Arthrex, INC. | $83.96 | 2025 | |
| Smith+Nephew, INC. | $72.28 | 2024-2025 | Pico 14 |
| Baudax Bio INC. | $46.73 | 2020-2022 | |
| Delcath Systems | $30.64 | 2025 | Hepzato Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fabbro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.